CatalYm has closed a €50 million ($59m) series B financing round to fund clinical studies of its immunotherapy targeting Growth Differentiation Factor 15 (GDF-15).
In amongst the big clinical trial readouts at ASCO, a new research project made its official debut with the ambitious goal of mapping cancer cells’ interactions with their
Health systems globally have reached a critical inflexion point, where ageing populations and tightening budgets mean we can no longer continue to purely treat late-stage symptomatic diseas